Drug Search Results
More Filters [+]

Eptacog alfa

Alternative Names: Eptacog alfa, eptacog alfa (activated), TQG-203, TQG203, TQG 203
Latest Update: 2023-10-03
Latest Update Note: News Article

Product Description

Novo Nordisk is developing eptacog alfa as a treatment for hemophilia A with inhibitor and hemophilia B with inhibitor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04768699)

Mechanisms of Action: FVIIa Replacer

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Egypt | European Medicines Agency | Finland | France | Germany | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Italy | Japan | Lebanon | Malaysia | Mexico | Netherlands | Pakistan | Philippines | Poland | Portugal | Russia | Slovakia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eptacog alfa

Countries in Clinic: Iran, Turkey

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Hemophilia A

Phase 1: Hemophilia B

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

UGA 2020-01

P1

Completed

Hemophilia B|Hemophilia A

2021-08-13

21%

2019-002854-22

P3

Active, not recruiting

Unknown

2021-03-04

UGA 2014-01

P3

Completed

Hemophilia A

2021-01-31

64%

Recent News Events